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Background. Recent work suggests that epigenetic diﬀerences may be associated with psychiatric disorders. Here we
investigate, in a community-based sample, whether methylation proﬁles distinguish between individuals with and
without lifetime depression. We also investigate the physiologic consequences that may be associated with these
proﬁles.
Method. Using whole blood-derived genomic DNA from a subset of participants in the Detroit Neighborhood
Health Study (DNHS), we applied methylation microarrays to assess genome-wide methylation proﬁles for over
14000 genes in 33 persons who reported a lifetime history of depression and 67 non-depressed adults. Bioinformatic
functional analyses were performed on the genes uniquely methylated and unmethylated in each group, and
inﬂammatory biomarkers [interleukin (IL)-6 and C-reactive protein (CRP)] were measured to investigate the possible
functional signiﬁcance of the methylation proﬁles observed.
Results. Uniquely unmethylated gene sets distinguished between those with versus without lifetime depression. In
particular, some processes (e.g. brain development, tryptophan metabolism) showed patterns suggestive of increased
methylation among individuals with depression whereas others (e.g. lipoprotein) showed patterns suggestive of
decreased methylation among individuals with depression. IL-6 and CRP levels were elevated among those with
lifetime depression and, among those with depression only, IL-6 methylation showed an inverse correlation with
circulating IL-6 and CRP.
Conclusions. Genome-wide methylation proﬁles distinguish individuals with versus without lifetime depression in a
community-based setting, and show coordinated signals with pathophysiological mechanisms previously implicated
in the etiology of this disorder. Examining epigenetic mechanisms in concert with other dynamic markers of
physiologic functioning should improve our understanding of the neurobiology of depression.
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Introduction
Epigenetic modiﬁcations regulate genetic function
through mechanisms that are independent of DNA
sequences. Although multiple types of epigenetic
modiﬁcations have been identiﬁed (Kim et al. 2009), all
involve chemical modiﬁcations that regulate chroma-
tin structure and/or DNA accessibility, which in turn
alter the transcriptional activity of the surrounding
loci. Methylation, the covalent modiﬁcation of DNA
whereby methyl groups are coupled to cytosine
residues at CpG sites, is perhaps the best studied
of these epigenetic mechanisms, due in part to its
tractability to study. In general, methylation and gene
expression are typically thought to show an inverse
correlation, such that increased methylation corre-
sponds to decreased gene expression and vice versa
(Egger et al. 2004).
As dynamic molecular markers that have been
shown to change with age (Bjornsson et al. 2008) and
experience (Kang et al. 2007), epigenetic signatures are
attractive candidates for elucidating the underlying
mechanisms of complex diseases (reviewed in Petronis,
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With respect to depression, animal models have
shown that early life events can change the methy-
lation levels of genes implicated in the neurobiology
of this disorder (i.e. NR3C1, 5-HTTLPR) (Weaver et al.
2004; Kinnally et al. 2010). In addition, work based
again on animal models has shown that these levels
can be altered through pharmacologic intervention
(Weaver et al. 2004, 2005), even in terminally diﬀer-
entiated, adult tissues. In humans, few studies have
been conducted that speciﬁcally address the link be-
tween methylation and depression. However, in vitro
investigation has suggested an association between a
lifetime history of major depressive disorder (MDD)
and methylation levels in the promoter region of
the serotonin transporter gene (SLC6A4; 5-HTTLPR)
(Philibert et al. 2008); and in vivo work suggests a
link between depressive symptoms and methylation at
this same locus (Olsson et al. 2010). Similarly, in vivo
work suggests an association between prenatal ex-
posure to maternal depression and postnatal methy-
lation levels in DNA from cord blood in the promoter
region of the NR3C1 gene (Oberlander et al. 2008).
Complementing these candidate gene examples,
approaches that investigate the entire genome have
reported numerous methylation diﬀerences in the
frontal cortices of patients aﬀected by schizophrenia
and bipolar disorder, compared to unaﬀected controls
(Mill et al. 2008). Importantly, many of these diﬀer-
ences occur in genes previously implicated in the
neurobiology of psychosis, including glutamatergic
and gamma-aminobutyric acid (GABA)ergic neuro-
transmission genes and loci involved in neuronal de-
velopment (Mill et al. 2008). Taken together, the results
from these early studies suggest that speciﬁc epi-
genetic proﬁles may be associated with mental illness;
however, to the best of our knowledge, such genome-
wide epigenetic proﬁles have yet to be reported for
depression.
An additional important mechanism to consider in
the etiology of depression is inﬂammation. Con-
siderable evidence has demonstrated a link between
inﬂammatory processes and depression (reviewed in
Maes, 1999; Dantzer et al. 2008). In particular, the role
of pro-inﬂammatory cytokines has received much at-
tention as a potential mediator of depression (Kronfol
& Remick, 2000; Kiecolt-Glaser & Glaser, 2002;
Schiepers et al. 2005; Irwin & Miller, 2007; Miller et al.
2009), with signiﬁcant increases in interleukin (IL)-6
and IL-1, for example, associated with the presence
the disorder (Maes et al. 1993a, 1995). In addition,
depression and other adverse psychiatric outcomes
are known to develop following therapeutic use of
cytokines such as IL-2 and interferon (IFN)-a (Kronfol
& Remick, 2000). From an epigenetic perspective,
inﬂammation is known to induce oxidative damage
(Backdahl et al. 2009), which can either reduce or
increase methylation: the former through the oxi-
dation of methyl groups, which renders methylated
CpG sites less recognizable to the enzyme that main-
tains methylation during mitosis; the latter through
the production of reactive halogen compounds that
mimic 5-methylcytosines in the binding of methyl-
binding proteins (Valinluck & Sowers, 2007). Indeed,
signiﬁcant correlations have been reported between
levels of global methylation and inﬂammatory bio-
markers [C-reactive protein (CRP) and IL-6] among
patients suﬀering from chronic kidney disease
(Stenvinkel et al. 2007). Nevertheless, research ex-
amining the link between depression and inﬂam-
mation, and between inﬂammation and methylation,
has been conducted primarily in experimental settings
(i.e. in clinical and animal model studies). This
highlights the importance of assessing these links in
community-based, epidemiologic studies.
To address these gaps in the literature, here we test
whether unique epigenetic proﬁles are associated with
depression in samples obtained from an ongoing,
prospective, longitudinal cohort: the Detroit Neigh-
borhood Health Study (DNHS). We used methylation
microarray technology to characterize genome-wide
methylation signatures among individuals with and
without lifetime depression in this community-based
sample. We then conducted bioinformatic analyses of
these microarray data to identify the biological path-
ways associated with the methylation proﬁles that
characterize those with and without the disorder.
Finally, to augment existing laboratory and clinical
research examining the link between depression and
inﬂammation, and to provide in vivo evidence for the
functional signiﬁcance of these depression-associated
methylation proﬁles, we investigated serum IL-6 and
CRP levels in these same individuals.
Method
A sample of 33 persons who reported a lifetime history
of depression and 67 non-depressed adults were
selected from an ongoing longitudinal study, the
DNHS. The DNHS is a survey-based investigation of
mental health correlates among Detroit residents. A
total of 1547 participants were surveyed during wave
1 of the study, each of whom received US$25 for their
participation in the survey. All survey participants
were oﬀered the opportunity to provide venepuncture
(VP) blood specimens for the biospecimen component
of the study (which included testing of immune and
inﬂammatory markers from serum and also genetic
testing of DNA) and received an additional US$25 if
they elected to do so. VP specimens were obtained
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eligible participants during wave 1 (n=501). For the
purposes of this study, 100 of these 501 participants
were selected midway through the wave 1 sample
collection eﬀort in order to conduct pilot testing of
epigenetic proﬁles associated with mental illness in
community-based settings.
Wave 1 survey participants were representative of
the Detroit population in terms of age, gender, race,
income, and educational attainment (ACS, 2009). The
100 participants in the current study were similar
to the full sample on these key sociodemographic
characteristics but were, on average, slightly younger
than individuals in the full survey sample (45.3 v. 50.6
years, p=0.003). As our subsample of 100 participants
for this study was selected speciﬁcally according to
presence of mental illness, the prevalence of de-
pression is much higher in our study sample (33%)
than in the full survey sample (17.6%).
Depressive symptoms were evaluated with the
nine-item depression scale of the Patient Health
Questionnaire (PHQ-9; Kroenke et al. 2001). Each of
the nine questions was scored as 0 (not at all) to 3
(nearly every day), such that scores ranged from 0 to
27 (Kroenke et al. 2001). Lifetime depression cases
were participants who reported depressed mood or
anhedonia, at least one additional symptom for
‘more than half the days’ for two or more weeks, and
whose symptoms occurred together. One symptom,
‘thoughts that you would be better oﬀ dead or of
hurting yourself in some way’, counted if present at
all, regardless of duration. The PHQ-9 in this study
had excellent internal consistency, with a=0.86.
In a clinical reappraisal performed on 51 random
participants from the larger study, comparing the
PHQ-9 to clinician-administered SCID, the measure
had a sensitivity of 0.60, speciﬁcity of 0.93, positive
predictive value of 0.67, negative predictive value of
0.90, and an area under the receiver operating charac-
teristic (ROC) curve of 0.76; these are comparable
to well-established brief assessments for depression
used in community-based samples such as the CIDI
(Andrews & Peters, 1998). Furthermore, low sensi-
tivity values for this instrument imply that our
prevalence estimates are conservative. Factor analysis
yielded one global dominant factor for the PHQ-9,
suggesting good symptom cohesiveness. This study
was approved by the Institutional Review Board (IRB)
of the University of Michigan, and all participants
provided written, informed consent.
Bisulﬁte conversion of previously extracted, whole
blood-derived genomic DNA from 100 individuals
and from control human methylated and non-
methylated DNA (Zymo Research, USA) was per-
formed on 1 mg of each sample using the EZ-96 DNA
Methylation
TM Kit (Zymo Research) following the
manufacturer’s recommended protocol. Four technical
replicates were also included, comprising duplicate
samples of two randomly selected individuals and
duplicate samples of the control human methylated
and unmethylated DNA. Bisulﬁte-converted DNA
was subsequently assessed for methylation status at
27578 CpG loci covering more than 14000 genes using
the humanmethylation27 (HM27) DNA Analysis
BeadChip (Illumina, USA). Samples were placed on
microarray chips without knowledge of depression
status; all replicates were placed on separate micro-
array chips. The resulting data were background
normalized using Illumina’s BeadStudio software and
exported for subsequent analysis using the R package
v. 2.9.0 and SAS software v. 9.2. Spearman correlation
coeﬃcients (r) of the two replicated samples were 0.81
and 0.89; control replicates showed r=0.96 (methyl-
ated controls) and r=0.98 (unmethylated controls).
DNA methylation b values range continuously
from 0 (completely unmethylated) to 1 (completely
methylated). The average b value for methylated con-
trol replicates was 0.93; for unmethylated control re-
plicates the average b value was 0.17. In this study,
probes with b values <0.2 were classiﬁed as un-
methylated, and probes with b values >0.8 were
classiﬁed as methylated. These values are conservative
compared to other cutoﬀs that have been used pre-
viously to determine methylated and unmethylated
sites on the HM27 BeadChip (Brunner et al. 2009) and
to the analogous percentage of methylation reference
(PMR) values found in the cancer literature (e.g.
Pike et al. 2008). Methylation levels were averaged
for each gene in each group (with and without
depression) and the number of shared versus uniquely
methylated/unmethylated genes was determined.
McNemar’s x
2 test was used to compare the pro-
portion of uniquely methylated and unmethylated
genes among depression-aﬀected versus depression-
unaﬀected individuals.
Functional analyses of genes uniquely methylated/
unmethylated in each group were performed using
the functional annotation clustering (FAC) tool in the
Database for Annotation, Visualization and Integrated
Discovery (DAVID; Huang et al. 2009). DAVID is a
publicly available resource that provides a compre-
hensive set of functional annotation tools to help in-
vestigators understand the biological meaning behind
large sets of genes. In this study, results were obtained
using the FAC tool, which clusters similar annotations
based on the co-occurrence of particular gene sets.
The tool also calculates an associated enrichment score
for each cluster based on the geometric mean of the
p values determined for each of its component anno-
tations (which is then reported in –log scale). For
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their default values and annotations were accessed as
indexed on 31 August 2009. Clusters were identiﬁed
by selecting the over-represented annotation that
conveyed the broadest biological meaning within each
FAC. Additional analyses of disease-related anno-
tations only were performed on the uniquely un-
methylated gene sets, with options otherwise set to
default values; the results for these analyses include
all annotations contained within each cluster. Pyro-
sequencing of two loci in subsets of 89 and 90 of the
100 individuals tested on the HM27 beadchip con-
ﬁrmed the direction of initial methylation results. In
addition, targeted DNA sequencing of three loci in
20 individuals conﬁrmed the existence of invariant
sequenceat the probe targetregions (Uddin et al. 2010).
Publicly accessible data on gene expression were
obtained from the National Center for Biotechnology
Information (NCBI) gene expression omnibus (GEO)
database. Whole blood-derived gene expression levels
from 40 samples were obtained for analysis from the
following datasets: GDS2952, GDS2519, GDS1331, and
GDS596. All samples were derived from healthy con-
trol individuals in these datasets. Commonly methyl-
ated and unmethylated probes were obtained from
our data as presented in dark grey in Fig. 1. RefSeqs
of the GEO data were obtained from Aﬀymetrix
NetAﬀx
TM Analysis Center batch query as of 27 July
2009 and then matched with the RefSeqs (accession
numbers) in the Illumina data for additional analysis.
Raw gene expression values of commonly methylated
and unmethylated probes were log base 2 transformed
and normalized by median centering. The values
were then averaged for each probe and a t test was
performed to compare the mean expression levels
between the two groups.
Peripheral blood mononuclear cells (PBMCs) were
isolated by centrifugation of whole blood and re-
suspended in 6 ml of freezing medium, 1 ml of which
was loaded into a packed cell volume (PCV) tube and
centrifuged in the tube at 2400 RCF for 1 min. PCV
tubes were then assessed for PBMC count using the
TPP Easy Read Ruler (MIDSCI, USA) and following
the manufacturer’s recommended protocols. IL-6 was
measured in serum in the same 100 individuals tested
on the HM27 BeadChips, using the QuantiGlo Human
IL-6 sandwich enzyme immunoassay kit (R&D
Systems, USA) and following the manufacturer’s rec-
ommended protocol. CRP was measured in serum in
99 of the 100 individuals (32 of 33 in the depression
aﬀected group) using the CRP Ultra Wide Range
Reagent Kit (Genzyme, USA) and following the manu-
facturer’s recommended protocols. Data were log
transformed prior to analysis to improve normality.
Results
Individuals diagnosed with depression did not diﬀer
signiﬁcantly from their unaﬀected counterparts with
respect to age, sex, race, education level, medication
use, smoking or drinking behavior, or PBMC count
(p>0.05; Table 1). By contrast, depression-aﬀected
individuals had fewer uniquely unmethylated and
methylated genes compared to depression-unaﬀected
individuals (Fig. 1); diﬀerences between the two
groups were statistically signiﬁcant (x
2=30.78, 1 df,
p<0.0001 for uniquely unmethylated gene com-
parisons and x
2=271.04, 1 df, p<0.0001 for uniquely
methylated gene comparisons). Gene expression
analysis of the genes commonly methylated and un-
methylated in both groups suggests that, in general,
methylated gene states correspond to lower gene
expression levels and unmethylated gene states cor-
respond to higher gene expression levels (Sup-
plementary Fig. S1).
The results for the top three FACs show that distinct
biological pathways are associated with the uniquely
methylated and unmethylated genes in each group
(Table 2; full FAC results are available as online
supplementary material, Tables S1–S4), with many
clusters reﬂecting pathways or processes known to be
altered among individuals with depression, particu-
larly among the uniquely unmethylated gene sets.
That individuals in both groups show these unique
methylation signatures suggests that, for some pro-
cesses (i.e. brain development, tryptophan meta-
bolism), individuals with depression typically show
higher methylation levels (and lower expression
levels) in the genes associated with that FAC.
Unmethylated genes
With
depression
Without
depression
With
depression
Without
depression
Methylated genes
107 9969 205 21 1401 329
Fig. 1. Number of methylated and umethylated genes
according to depression status. White indicates the genes
uniquely methylated or unmethylated among individuals
with lifetime depression, light grey indicates the genes
uniquely methylated or unmethylated among individuals
without lifetime depression, and dark grey indicates the
genes commonly methylated or unmethylated in both
groups. Methylated genes were deﬁned as those genes with
average b values of >0.8, and unmethylated genes were
deﬁned as those genes with average b values of <0.2.
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Lifetime depression status Group
comparison
testa
p
With
depression
Without
depression
Sex
Male 10 30 0.16
Female 23 37
Age (years) 43.5 (11.9) 46.2 (18.7) 0.39
Race
White 5 9 0.08
Black 23 56
Other 5 2
Education
Less than high school 5 9 1.00
High school or more 28 58
Smoking
Ever smoked 17 41 0.36
Never smoke 16 26
Alcohol consumption
Ever drank 25 52 0.84
Never drank 8 15
Taking any medicationsb
None 17 35 0.95
At least one 16 32
Anti-infective
No 32 63 1.00
Yes 1 4
Biologic/immunologic
No 33 66 1.00
Yes 0 1
Anti-infective/biologic/immunologic
No 32 62 0.66
Yes 1 5
Antidepressants
No 30 65 0.33
Yes 3 2
Anti-anxiety
No 30 66 0.10
Yes 3 1
Anti-psychotic
No 32 65 1.00
Yes 1 2
Antidepressants/anti-anxiety/anti-psychotic
No 28 62 0.29
Yes 5 5
PBMC count 24.54 (9.13) 22.75 (7.46) 0.30
Serum IL-6 levelsc 6.25 (13.62) 3.38 (6.41) 0.26
Serum CRP levelsc 11.72 (18.67) 4.15 (4.78) 0.03
PBMC, Peripheral blood mononuclear cell; IL-6, interleukin-6; CRP, C-reactive protein.
Values given as n or mean (standard deviation).
aStudent’s t test for age and x
2 tests for the other variables.
bMedications were classiﬁed according to the Medispan1 database.
cLevels are reported in untransformed units.
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drolase activity), the results suggest that individuals
with depression typically show lower methylation
levels (and higher expression levels) in the genes as-
sociated with that FAC. Analyses of disease-related
annotations among the unmethylated gene sets show
FACs composed almost exclusively of psychopath-
ology-associated disease classes in the depression-
unaﬀected group (Table 3), suggesting again that
individuals with depression possess higher methyla-
tion levels in these psychopathology-associated gene
sets. No disease-related FACs (involving psychopath-
ology or any other disease class) were identiﬁed from
the uniquely unmethylated genes among individuals
with depression.
Fig. 2 shows average IL-6 and CRP levels in those
with and without lifetime depression. Average IL-6
levels were higher in the depression-aﬀected group
(Welch’s t=1.91, df=58, p=0.06). Average CRP levels
were signiﬁcantly higher in this same group (Welch’s
t=2.95, df=59, p<0.01). Among those with lifetime
depression only, there was a signiﬁcant inverse
correlation between methylation and serum levels of
IL-6 (Pearson r=x0.54, p=0.001), and a signiﬁcant
inverse correlation between methylation of IL-6 and
serum levels of CRP (Pearson r=x0.48, p=0.006).
Table 2. Functional annotation cluster analyses of uniquely methylated and unmethylated genesa
Group
Uniquely unmethylated Uniquely methylated
Cluster
No. of
genes
Enrichment
score Cluster
No. of
genes
Enrichment
score
With
depression
Multicellular organismal
development
36 2.06 Protease 11 0.78
Lipoprotein 7 1.4 Metabolic process 15 0.52
Hydrolase activity, acting
on ester bonds
10 1.12 Cell development 3 0.49
Without
depression
Brain development 11 1.22 Signal 127 2.73
Tryptophan metabolism 12 1.12 Lipocalin 9 2.47
Neuromuscular process 6 0.99 Tissue development 12 2.3
aAll genes are identiﬁed in terms of DAVID IDs; genes can appear in more than one cluster.
Table 3. Disease-based functional annotation clustering results of genes uniquely unmethylated among individuals without lifetime
depression
Functional cluster 1 Enrichment score: 0.89 No. of genesa in cluster: 5
Category Annotation No. of genes in annotation
GENETIC_ASSOCIATION_DB_DISEASE Alcoholism 4
GENETIC_ASSOCIATION_DB_DISEASE Attention deﬁcit disorder, conduct
disorder, oppositional deﬁant disorder
3
GENETIC_ASSOCIATION_DB_DISEASE Bipolar disorder 4
GENETIC_ASSOCIATION_DB_DISEASE_CLASS CHEMDEPENDENCY 4
Functional cluster 2 Enrichment score: 0.71 No. of genes in cluster: 8
Category Annotation No. of genes in annotation
GENETIC_ASSOCIATION_DB_DISEASE Cognitive function 3
GENETIC_ASSOCIATION_DB_DISEASE Parkinson’s disease 4
GENETIC_ASSOCIATION_DB_DISEASE_CLASS NEUROLOGICAL 8
Functional cluster 3 Enrichment score: 0.28 No. of genes in cluster: 10
Category Annotation No. of genes in annotation
GENETIC_ASSOCIATION_DB_DISEASE Bipolar disorder 4
GENETIC_ASSOCIATION_DB_DISEASE_CLASS PSYCHIATRIC 9
GENETIC_ASSOCIATION_DB_DISEASE Schizophrenia 4
GENETIC_ASSOCIATION_DB_DISEASE_CLASS PHARMACOGENOMIC 4
aAll genes are identiﬁed in terms of DAVID IDs; genes can appear in more than one cluster.
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methylation and serum levels for CRP.
Discussion
Drawing on samples obtained from an ongoing,
longitudinal epidemiologic study, our study docu-
ments, for the ﬁrst time, genome-wide diﬀerences in
methylation proﬁles among individuals with and
without lifetime depression in a community-based
setting. We ﬁnd that genes uniquely unmethylated
in each of the two groups show evidence for the
involvement of inﬂammatory-related pathways and
processes previously implicated in depression, and
conﬁrm the functional signiﬁcance of these results by
demonstrating elevated levels of two inﬂammatory
markers, IL-6 and CRP, among those with lifetime
depression. This functional relationship was further
corroborated by the ﬁnding of an inverse correlation
between methylation of IL-6 CpG and circulating IL-6
and CRP levels among those with lifetime depression.
Among individuals with lifetime depression, we
observed a signal of lipoprotein-related functions
in the uniquely unmethylated gene set (Table 2). In
humans, studies based on peripheral blood have
shown increased levels of lipid peroxidation among
patients with depression (Galecki et al. 2007). Simi-
larly, work based on gene expression microarrays has
identiﬁed depression-associated diﬀerences in blood
gene expression patterns for loci involved in lipid
metabolism (Kalman et al. 2005). Indeed, depression
has been characterized as an immune response direc-
ted against disrupted lipid membrane components
and by-products of lipid peroxidation (Maes, 2008).
The epigenetic signal observed here is thus consistent
with previous reports of lipid-related diﬀerences
associated with depression.
Among individuals without lifetime depression,
the topmost FAC pertains to brain development and
neurogenesis-related functions (Table 2; Table S3).
Recent work focusing on the action of antidepressants
in both rodents and humans suggests that impair-
ments in neurogenesis may play a contributing role to
the reduction in cell numbers and morphological
plasticity associated with depression (reviewed in
Manji et al. 2000a,b). In addition, the identiﬁcation of
tryptophan metabolism among the top three func-
tional clusters in the depression-unaﬀected group is
consistent with previous reports regarding the role of
tryptophan, a precursor of serotonin, in depressed in-
dividuals. In experimental studies of patients whose
depression is currently in remission, patients who
ingest a tryptophan-deﬁcient amino acid mixture
that transiently decreases serotonin levels in the brain
often experience a brief relapse of symptoms during
tryptophan depletion (aan het Rot et al. 2009).
Our ﬁndings of higher IL-6 levels and signiﬁcantly
higher CRP levels in those with depression are also
consistent with previous work conducted in both
clinical and community settings (e.g. Trzonkowski
et al. 2004; Ranjit et al. 2007; Gimeno et al. 2009; and
reviewed in Howren et al. 2009). Unique to this study,
however, is the pairing of methylation and inﬂamma-
tory marker testing in the same individuals, which
enabled us to infer potential functional consequences
of the methylation diﬀerences that distinguished those
with and without depression. IL-6 is a cytokine that
plays a central role in a variety of inﬂammation-
associated disease states, including depression (Elenkov,
2008). CRP is a protein found in the blood, the levels of
which rise in response to inﬂammation (speciﬁcally,
due to a rise in the plasma concentration of IL-6)
(Pepys & Hirschﬁeld, 2003). As noted in the introduc-
tion, a wealth of evidence suggests that inﬂammation
may increase the risk of major depressive episodes
(Maes et al. 1993c, 2009; Sluzewska et al. 1996; Maes,
1999, 2008; Dantzer et al. 2008). This increased risk has
been attributed in particular to a reduction in plasma
tryptophan levels previously reported among indi-
viduals with depression (Anderson et al. 1990; Maes
et al. 1993b). TRP is metabolized via two main path-
ways, one that produces serotonin through trypto-
phan hydroxylase enzymatic activity, and another that
produces kynurenin and kynurenic acid through the
action of tryptophan 2,3-dioxygenase and indoleamine
2,3-dioxygenase (IDO) (Myint & Kim, 2003; Leonard &
Myint, 2009). Notably, IDO is expressed in all organs,
including the brain (Dantzer et al. 2008), and cytokines
can enhance IDO activity (Hu et al. 1995; Babcock
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Fig. 2. Box plot of log-transformed interleukin (IL)-6 and
C-reactive protein (CRP) serum levels in those with versus
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median IL-6 and CRP levels in each group (black horizontal
bar) and also the range of the values, with the top and bottom
whiskers representing the maximum and minimum values,
respectively.
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proposed to result in an inﬂammation-induced de-
pletion of plasma tryptophan that ultimately induces
serotonin depletion in the brain of those aﬀected by
depression (the so-called ‘neurodegeneration hypoth-
esis’ of depression; Myint & Kim, 2003). Other work,
however, suggests that in the case of depression, the
disorder itself may be the cause of increased inﬂam-
mation (reviewed in Miller et al. 2009) and the sickness
behavior that often accompanies it (Gold & Irwin,
2009). Although the direction of the inﬂammation/
depression relationship has yet to be fully elucidated
(Howren et al. 2009), lowered plasma tryptophan has
been labeled an ‘inﬂammatory biomarker of de-
pression’ (Maes et al. 1997; Maes, 2008). In this study,
we saw evidence for unique activation of this pathway
in our epigenetic results among those unaﬀected by
depression (Table 2), suggesting relatively increased
expression of related genes in this group, and con-
sistent with the decreased activity of inﬂammatory
markers we observed in comparison to those with
depression. Taken together, these results suggest that
the etiology of depression involves dysregulated bio-
logic processes that are altered across multiple levels
of organization, from molecular-level changes in
methylation proﬁles observed in blood-derived DNA
to systemic changes in pro-inﬂammatory cytokine
signaling pathways that, although observed in the
periphery, are known to be capable of aﬀecting
neurogenesis in the central nervous system (CNS) and
are related to disruptions in neuroplasticity in mood-
relevant brain regions (reviewed in Miller et al. 2009).
Finally, our disease-related analyses identiﬁed three
clusters predominantly comprising psychopathology-
associated functional annotations (Table 3). Included
in these clusters (and also those in Table 2) are
genes previously implicated in the etiology of de-
pression, including monoamine oxidase A (MAOA)
and solute carrier family 6 (SLC6A3), in addition to
other genes belonging to gene families also previously
implicated in depression [e.g. GABA A receptor genes,
5-hydroxytryptamine (serotonin) receptor genes] or
other psychiatric disorders (e.g. regulator of G-protein
signaling 4, RGS4).
Several limitations should be considered when inter-
preting these ﬁndings. First, based on the current,
cross-sectional analyses, it is not possible to determine
whether the observed depression-associated methyla-
tion and inﬂammatory marker patterns are indicative
of changes due to the disorder, or whether they are
instead reﬂective of underlying biologic vulnera-
bilities among depression-aﬀected individuals that
existed prior to the disorder; additional, longitudinal
studies are needed to address this issue. Second,
methylation levels are known to vary among tissues
and cells types (Eckhardt et al. 2006). Our reliance
on DNA from whole blood to assess methylation
patterns, rather than speciﬁc cell types within the
blood, meant that we were unable to determine
blood cell-speciﬁc diﬀerences in methylation status,
which would have to be accounted for when replicat-
ing the current ﬁndings in other, longitudinal cohorts.
Similarly, our necessary reliance on peripheral tissues
limits the inferences that can be drawn regarding
pathways involving the brain. Nevertheless, a grow-
ing body of research conﬁrms the promise of using
peripheral blood to make inferences about brain-
related processes (Gladkevich et al. 2004; Wrona, 2006;
Le-Niculescu et al. 2009), which bodes well for the
expanded use of this tissue in large epidemiologic
studies such as the DNHS. Finally, given previous
reports of race/ethnic diﬀerences in methylation
levels at speciﬁc loci (e.g. Lee et al. 2007) and the
overwhelmingly African-American heritage of indi-
viduals who provided samples for this study (79%),
the results from this work may not be generalizable to
other populations.
Despite these limitations, our results provide the
ﬁrst report of peripheral epigenomic proﬁles as-
sociated with depression in a community setting,
and provide a ﬁrst step toward integrating the func-
tional signiﬁcance of these proﬁles with additional,
independent physiologic measures of inﬂammatory
markers. Future work should consider epigenetic
mechanisms in the search to better understand the
neurobiology of depression.
Note
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
psm).
Acknowledgments
This work was supported by National Institutes
of Health (NIH) grants DA022720, DA022720-S1,
RC1MH088283, MH078928 and MH07627. Additional
support was provided by the Robert Wood Johnson
Health and Society Scholars Small Grant Program
and the University of Michigan OVPR Faculty Grants
and Awards Program (M.U.); and by the Wayne
State University Research Excellence Fund (D.E.W.).
Funding for IL-6 and CRP testing was generously
provided by the University of Michigan Nathan Shock
Center, Grant AG013283 (A.E.A.).
Declaration of Interest
None.
1004 M. Uddin et al.References
aan het Rot M, Mathew SJ, Charney DS (2009).
Neurobiological mechanisms in major depressive disorder.
Canadian Medical Association Journal 180, 305–313.
ACS (2009). 2005–2007 American Community Survey 3-Year
Estimates. U.S. Census Bureau: Washington, DC.
Anderson IM, Parry-Billings M, Newsholme EA,
Poortmans JR, Cowen PJ (1990). Decreased plasma
tryptophan concentration in major depression:
relationship to melancholia and weight loss. Journal of
Aﬀective Disorders 20, 185–191.
Andrews G, Peters L (1998). The psychometric properties
of the Composite International Diagnostic Interview.
Social Psychiatry and Psychiatric Epidemiology 33, 80–88.
Babcock TA, Carlin JM (2000). Transcriptional activation
of indoleamine dioxygenase by interleukin 1 and tumor
necrosis factor alpha in interferon-treated epithelial cells.
Cytokine 12, 588–594.
Backdahl L, Bushell A, Beck S (2009). Inﬂammatory
signalling as mediator of epigenetic modulation in
tissue-speciﬁc chronic inﬂammation. International Journal
of Biochemistry and Cell Biology 41, 176–184.
Bjornsson HT, Sigurdsson MI, Fallin MD, Irizarry RA,
Aspelund T, Cui H, Yu W, Rongione MA, Ekstrom TJ,
Harris TB, Launer LJ, Eiriksdottir G, Leppert MF,
Sapienza C, Gudnason V, Feinberg AP (2008).
Intra-individual change over time in DNA methylation
with familial clustering. Journal of the American Medical
Association 299, 2877–2883.
Brunner AL, Johnson DS, Kim SW, Valouev A, Reddy TE,
Neﬀ NF, Anton E, Medina C, Nguyen L, Chiao E,
Oyolu CB, Schroth GP, Absher DM, Baker JC, Myers RM
(2009). Distinct DNA methylation patterns characterize
diﬀerentiated human embryonic stem cells and developing
human fetal liver. Genome Research 19, 1044–1056.
Dantzer R, O’Connor JC, Freund GG, Johnson RW,
Kelley KW (2008). From inﬂammation to sickness and
depression: when the immune system subjugates the
brain. Nature Reviews Neuroscience 9, 46–56.
Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J,
Burger M, Burton J, Cox TV, Davies R, Down TA,
Haeﬂiger C, Horton R, Howe K, Jackson DK, Kunde J,
Koenig C, Liddle J, Niblett D, Otto T, Pettett R, Seemann
S, Thompson C, West T, Rogers J, Olek A, Berlin K,
Beck S (2006). DNA methylation proﬁling of human
chromosomes 6, 20 and 22. Nature Genetics 38, 1378–1385.
Egger G, Liang G, Aparicio A, Jones PA (2004). Epigenetics
in human disease and prospects for epigenetic therapy.
Nature 429, 457–463.
Elenkov IJ (2008). Neurohormonal-cytokine interactions:
implications for inﬂammation, common human diseases
and well-being. Neurochemistry International 52, 40–51.
Galecki P, Kedziora J, Florkowski A, Galecka E (2007).
Lipid peroxidation and copper-zinc superoxide dismutase
activity in patients treated with ﬂuoxetine during the
ﬁrst episode of depression [in Polish]. Psychiatria Polska 41,
615–624.
Gimeno D, Kivimaki M, Brunner EJ, Elovainio M,
De Vogli R, Steptoe A, Kumari M, Lowe GD, Rumley A,
Marmot MG, Ferrie JE (2009). Associations of C-reactive
protein and interleukin-6 with cognitive symptoms of
depression: 12-year follow-up of the Whitehall II study.
Psychological Medicine 39, 413–423.
Gladkevich A, Kauﬀman HF, Korf J (2004). Lymphocytes
as a neural probe: potential for studying psychiatric
disorders. Progress in Neuropsychopharmacology and
Biological Psychiatry 28, 559–576.
Gold SM, Irwin MR (2009). Depression and immunity:
inﬂammation and depressive symptoms in multiple
sclerosis. Immunology and Allergy Clinics of North America
29, 309–320.
Howren MB, Lamkin DM, Suls J (2009). Associations of
depression with C-reactive protein, IL-1, and IL-6:
a meta-analysis. Psychosomatic Medicine 71, 171–186.
Hu B, Hissong BD, Carlin JM (1995). Interleukin-1 enhances
indoleamine 2,3-dioxygenase activity by increasing speciﬁc
mRNA expression in human mononuclear phagocytes.
Journal of Interferon and Cytokine Research 15, 617–624.
Huang DW, Sherman BT, Lempicki RA (2009). Systematic
and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nature Protocols 4, 44–57.
Irwin MR, Miller AH (2007). Depressive disorders and
immunity: 20 years of progress and discovery. Brain
Behavior and Immunity 21, 374–383.
Kalman J, Palotas A, Juhasz A, Rimanoczy A, Hugyecz M,
Kovacs Z, Galsi G, Szabo Z, Pakaski M, Feher LZ,
Janka Z, Puskas LG (2005). Impact of venlafaxine on gene
expression proﬁle in lymphocytes of the elderly with major
depression – evolution of antidepressants and the role of
the ‘neuro-immune’ system. Neurochemical Research 30,
1429–1438.
Kang HJ, Adams DH, Simen A, Simen BB, Rajkowska G,
Stockmeier CA, Overholser JC, Meltzer HY, Jurjus GJ,
Konick LC, Newton SS, Duman RS (2007). Gene
expression proﬁling in postmortem prefrontal cortex of
major depressive disorder. Journal of Neuroscience 27,
13329–13340.
Kiecolt-Glaser JK, Glaser R (2002). Depression and immune
function: central pathways to morbidity and mortality.
Journal of Psychosomatic Research 53, 873–876.
Kim JK, Samaranayake M, Pradhan S (2009). Epigenetic
mechanisms in mammals. Cellular and Molecular Life
Sciences 66, 596–612.
Kinnally EL, Capitanio JP, Leibel R, Deng L, Leduc C,
Haghighi F, Mann JJ (2010). Epigenetic regulation of
serotonin transporter expression and behavior in infant
rhesus macaques. Genes, Brain and Behavior 6, 575–582.
Kroenke K, Spitzer RL, Williams JB (2001). The PHQ-9:
validity of a brief depression severity measure. Journal of
General Internal Medicine 16, 606–613.
Kronfol Z, Remick DG (2000). Cytokines and the brain:
implications for clinical psychiatry. American Journal of
Psychiatry 157, 683–694.
Lee JS, Lo PK, Fackler MJ, Argani P, Zhang Z,
Garrett-Meyer E, Sukumar S (2007). A comparative study
of Korean with Caucasian breast cancer reveals frequency
of methylation in multiple genes correlates with breast
cancer in young, ER, PR-negative breast cancer in
Korean women. Cancer Biology and Therapy 6, 1114–1120.
Epigenetics of depression in a community-based setting 1005Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD,
Edenberg HJ, Tsuang MT, Salomon DR, Nurnberger Jr.
JI, Niculescu AB (2009). Identifying blood biomarkers for
mood disorders using convergent functional genomics.
Molecular Psychiatry 14, 156–174.
Leonard BE, Myint A (2009). The psychoneuroimmunology
of depression. Human Psychopharmacology 24, 165–175.
Maes M (1999). Major depression and activation of the
inﬂammatory response system. Advances in Experimental
Medicine and Biology 461, 25–46.
Maes M (2008). The cytokine hypothesis of depression:
inﬂammation, oxidative & nitrosative stress (IO&NS) and
leaky gut as new targets for adjunctive treatments in
depression. Neuroendocrinology Letters 29, 287–291.
Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E (1993a).
Interleukin-1 beta: a putative mediator of HPA axis
hyperactivity in major depression? American Journal of
Psychiatry 150, 1189–1193.
Maes M, Meltzer HY, Bosmans E, Bergmans R,
Vandoolaeghe E, Ranjan R, Desnyder R (1995).
Increased plasma concentrations of interleukin-6, soluble
interleukin-6, soluble interleukin-2 and transferrin
receptor in major depression. Journal of Aﬀective Disorders
34, 301–309.
Maes M, Meltzer HY, Scharpe S, Bosmans E, Suy E,
De Meester I, Calabrese J, Cosyns P (1993b). Relationships
between lower plasma L-tryptophan levels and immune-
inﬂammatory variables in depression. Psychiatry Research
49, 151–165.
Maes M, Scharpe S, Meltzer HY, Bosmans E, Suy E,
Calabrese J, Cosyns P (1993c). Relationships between
interleukin-6 activity, acute phase proteins, and function
of the hypothalamic-pituitary-adrenal axis in severe
depression. Psychiatry Research 49, 11–27.
Maes M, Verkerk R, Vandoolaeghe E, Van Hunsel F,
Neels H, Wauters A, Demedts P, Scharpe S (1997).
Serotonin-immune interactions in major depression:
lower serum tryptophan as a marker of an immune-
inﬂammatory response. European Archives of Psychiatry
and Clinical Neuroscience 247, 154–161.
Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J,
Perini G, Kubera M, Bob P, Lerer B, Maj M (2009).
The inﬂammatory & neurodegenerative (I&ND)
hypothesis of depression: leads for future research and
new drug developments in depression. Metabolic Brain
Disease 24, 27–53.
Manji HK, Moore GJ, Chen G (2000a). Clinical and
preclinical evidence for the neurotrophic eﬀects of mood
stabilizers: implications for the pathophysiology and
treatment of manic-depressive illness. Biological Psychiatry
48, 740–754.
Manji HK, Moore GJ, Rajkowska G, Chen G (2000b).
Neuroplasticity and cellular resilience in mood disorders.
Molecular Psychiatry 5, 578–593.
Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S,
Bouchard L, Jia P, Assadzadeh A, Flanagan J,
Schumacher A, Wang SC, Petronis A (2008). Epigenomic
proﬁling reveals DNA-methylation changes associated
with major psychosis. American Journal of Human Genetics
82, 696–711.
Miller AH, Maletic V, Raison CL (2009). Inﬂammation and
its discontents: the role of cytokines in the
pathophysiology of major depression. Biological Psychiatry
65, 732–741.
Myint AM, Kim YK (2003). Cytokine-serotonin interaction
through IDO: a neurodegeneration hypothesis of
depression. Medical Hypotheses 61, 519–525.
Oberlander TF, Weinberg J, Papsdorf M, Grunau R,
Misri S, Devlin AM (2008). Prenatal exposure to maternal
depression, neonatal methylation of human glucocorticoid
receptor gene (NR3C1) and infant cortisol stress responses.
Epigenetics 3, 97–106.
Olsson CA, Foley DL, Parkinson-Bates M, Byrnes G,
McKenzie M, Patton GC, Morley R, Anney RJ,
Craig JM, Saﬀery R (2010). Prospects for epigenetic
research within cohort studies of psychological disorder:
a pilot investigation of a peripheral cell marker of
epigenetic risk for depression. Biological Psychology 83,
159–165.
Pepys MB, Hirschﬁeld GM (2003). C-reactive protein:
a critical update. Journal of Clinical Investigation 111,
1805–1812.
Petronis A (2010). Epigenetics as a unifying principle in
the aetiology of complex traits and diseases. Nature 465,
721–727.
Philibert RA, Sandhu H, Hollenbeck N, Gunter T,
Adams W, Madan A (2008). The relationship of 5HTT
(SLC6A4) methylation and genotype on mRNA expression
and liability to major depression and alcohol dependence
in subjects from the Iowa Adoption Studies. American
Journal of Medical Genetics. Part B, Neuropsychiatric Genetics
147B, 543–549.
Pike BL, Greiner TC, Wang X, Weisenburger DD, Hsu YH,
Renaud G, Wolfsberg TG, Kim M, Weisenberger DJ,
Siegmund KD, Ye W, Groshen S, Mehrian-Shai R,
Delabie J, Chan WC, Laird PW, Hacia JG (2008). DNA
methylation proﬁles in diﬀuse large B-cell lymphoma and
their relationship to gene expression status. Leukemia 22,
1035–1043.
Ptak C, Petronis A (2010). Epigenetic approaches to
psychiatric disorders. Dialogues in Clinical Neuroscience 12,
25–35.
Ranjit N, Diez-Roux AV, Shea S, Cushman M, Seeman T,
Jackson SA, Ni H (2007). Psychosocial factors and
inﬂammation in the multi-ethnic study of atherosclerosis.
Archives of Internal Medicine 167, 174–181.
Schiepers OJ, Wichers MC, Maes M (2005). Cytokines and
major depression. Progress in Neuropsychopharmacology and
Biological Psychiatry 29, 201–217.
Sluzewska A, Rybakowski J, Bosmans E, Sobieska M,
Berghmans R, Maes M, Wiktorowicz K (1996). Indicators
of immune activation in major depression. Psychiatry
Research 64, 161–167.
Stenvinkel P, Karimi M, Johansson S, Axelsson J,
Suliman M, Lindholm B, Heimburger O, Barany P,
Alvestrand A, Nordfors L, Qureshi AR, Ekstrom TJ,
Schalling M (2007). Impact of inﬂammation on
epigenetic DNA methylation – a novel risk factor for
cardiovascular disease? Journal of Internal Medicine 261,
488–499.
1006 M. Uddin et al.Trzonkowski P, Mysliwska J, Godlewska B, Szmit E,
Lukaszuk K, Wieckiewicz J, Brydak L, Machala M,
Landowski J, Mysliwski A (2004). Immune consequences
of the spontaneous pro-inﬂammatory status in depressed
elderly patients. Brain, Behavior, and Immunity 18, 135–148.
Uddin M, Aiello AE, Wildman DE, Koenen KC, Pawelec G,
de Los Santos R, Goldmann E, Galea S (2010). Epigenetic
and immune function proﬁles associated with
posttraumatic stress disorder. Proceedings of the National
Academy of Sciences USA 107, 9470–9475.
Valinluck V, Sowers LC (2007). Endogenous cytosine
damage products alter the site selectivity of human DNA
maintenance methyltransferase DNMT1. Cancer Research
67, 946–950.
Weaver IC, Cervoni N, Champagne FA, D’Alessio AC,
Sharma S, Seckl JR, Dymov S, Szyf M, Meaney MJ (2004).
Epigenetic programming by maternal behavior.
Nature Neuroscience 7, 847–854.
Weaver IC, Champagne FA, Brown SE, Dymov S, Sharma S,
Meaney MJ, Szyf M (2005). Reversal of maternal
programming of stress responses in adult oﬀspring
through methyl supplementation: altering epigenetic
marking later in life. Journal of Neuroscience 25,
11045–11054.
Wrona D (2006). Neural-immune interactions: an integrative
view of the bidirectional relationship between the brain
and immune systems. Journal of Neuroimmunology 172,
38–58.
Epigenetics of depression in a community-based setting 1007